Summary
Methysergide depresses the contractile effects of 5-hydroxytryptamine (5-HT) in bovine large coronary arteries devoid of endothelium.
-
1.
The IC50 of methysergide for depression of the response to 5-HT was (-log mol/l) 9.8. A low sensitivity contractile effect of 5-HT was not influenced by 1–1,000 nmol/l methysergide. The maximum, force of this residual response is approximately 1/3 of the maximum force elicited by 5-HT in the absence of methysergide.
-
2.
Ketanserin restored the 5-HT-induced contraction depressed by methysergide. In the presence of 0.1 μmol/l ketanserin, methysergide caused depression of the 5-HT-induced effects with an IC50 (-log mol/l) of 6.5 without affecting the residual response.
-
3.
We propose that methysergide depresses 5-HT-induced contractions by acting on an allosteric site. The effect of binding of methysergide to the allosteric site would lead to a conformational change of the 5-HT2-receptor, thereby only allowing the production of a residual 5-HT-induced contraction. Ketanserin competes with high affinity not only with 5-HT for the 5-HT2-receptor but also with methysergide for the allosteric site, thus shifting the receptor back into its original conformation. The affinity estimate of ketanserin for the allosteric site yielded a K B (-log mol/l) of 10.3.
-
4.
Ketanserin (1–1,000 nmol/l) antagonized the contractile effects of 5-HT with a potency expected from its affinity for 5-HT2-receptors (-log K B, mol/l 9.4). However, micromolar concentrations of ketanserin antagonized the effects of 5-HT less than expected from its affinity for 5-HT2-receptors. We suggest the existence of a low affinity receptor for ketanserin activated by 5-HT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonism. Br J Pharmacol 14:48–58
Blinks JR (1965) Convenient apparatus for recording contractions of isolated muscle. J Appl Physiol 20:755–757
Cocks TM, Angus JA (1983) Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305:627–630
De Caterina R, Carpeggiani C, L'Abbate A (1984) A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation 69:889–894
Fozard JR (1982) Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4:829–838
Freedman SB, Chierchia S, Rodriguez-Plaza L, Burgiardini R, Smith G, Maseri A (1984) Ergonovine-induced myocardial ischemia: no role for serotonergic receptors? Circulation 70:178–183
Frenken M, Kaumann AJ (1984a) Interaction of ketanserin and its metabolite ketanserinol with 5-HT2-receptors in pulmonary and coronary arteries of calf. Naunyn-Schmiedeberg's Arch Pharmacol 326:334–339
Frenken M, Kaumann AJ (1984b) Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions in large coronary arteries of the dog. Naunyn-Schmiedeberg's Arch Pharmacol 328:301–303
Frenken M, Kaumann AJ (1984c) Interconversion between two 5-HT2-receptor states in large coronary, artery (CA) of calf. Proceedings of the 9th International Congress of Pharmacology, London, UK, p 170 P
Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature 305:140–142
Kaumann AJ (1983) Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5-HT2-receptors. Naunyn-Schmiedeberg's Arch Pharmacol 323:149–154
Kaumann AJ, Breuer H-WM, Arnold G (1982) Heterogeneous spare receptors for serotonin (5-HT) in bovine coronary arteries. Pflügers Arch 392:R36
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberg J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2-receptors. Life Sci 28:1015–1022
Leysen JE, Niemegeers CJE, van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301–314
Nahorski SR, Willcocks AL (1983) Interactions of β-adrenoceptor antagonists with 5-hydroxytryptamine receptor subtypes in rat cerebral cortex. Br J Pharmacol 78: 107P
Peroutka ST, Snyder SH (1979) Multiple serotonin receptors: Differential binding of (3H)5-hydroxytryptamine, (3H)lysergic acid diethylamine and (3H)spiroperidol. Mol Pharmacol 16:687–699
Van Nueten JM, Janssen PAJ, van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981) Vascular effects of ketanserin (R 41468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218:217–230
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaumann, A.J., Frenken, M. A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Naunyn-Schmiedeberg's Arch. Pharmacol. 328, 295–300 (1985). https://doi.org/10.1007/BF00515556
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00515556